

# Memo

**Date:** January 2011

**To:** Aurora Physicians

**From:** Gail Buenger, JD, Institutional Official  
Martin Oaks, Ph.D., Senior Chair Aurora IRB Biomedical  
Dennis Baumgardner, MD, Chair Aurora IRB Biomedical  
Cynthia Valentin, PhD, Chair Aurora IRB Behavioral  
Brian Weir, RPh, Chair Aurora IRB Biomedical

**Re:** Emergency Use of Investigational Drugs/Biologics



Research Subject  
Protection Program

This memo is intended to summarize FDA's requirements regarding emergency use of an investigational drug or biologic. To discuss a specific situation, contact Lori Roesch, RSPP Manager by calling 414.219.7740 or by paging 414.222.4792.

For the Aurora IRB policy, refer to "**Emergency Single Time Use Of An Investigational Article (Drug, Device, Biologic)**" (EU 1301) available on the RSPP/IRB web site [www.aurora.org/irb](http://www.aurora.org/irb).

**Emergency use** is defined as the use of an investigational product with a human subject in a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain IRB approval [21 CFR 56.102(d)]. The emergency use provision in the FDA regulations [21 CFR 56.104(c)] is an exemption from prior review and approval by the IRB. The exemption, which may not be used unless all of the conditions described in 21 CFR 56.102(d) exist, allows for one emergency use of a test article without prospective IRB review. FDA regulations require that any subsequent use of the investigational product at the institution have prospective IRB review and approval. FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue.

**Life-threatening**, for the purposes of section 56.102(d), includes the scope of both life-threatening and severely debilitating, as defined below.

- **Life-threatening** means diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival. The criteria for life-threatening do not require the condition to be immediately life-threatening or to immediately result in death. Rather, the subjects must be in a life-threatening situation requiring intervention before review at a convened meeting of the IRB is feasible.
- **Severely debilitating** means diseases or conditions that cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke.

Aurora IRB policy requires that the IRB be notified prior to such use whenever possible; however, this notification should not be construed as an IRB approval. Notification should be

used by the IRB to initiate tracking to ensure that the investigator files a report within the five day time-frame required by 21 CFR 56.104(c). The FDA regulations do not provide for expedited IRB approval in emergency situations. Therefore, "interim," "compassionate," "temporary" or other terms for an expedited approval process are not authorized. An IRB must either convene and give "full board" approval of the emergency use or, if the conditions of 21 CFR 56.102(d) are met and it is not possible to convene a quorum within the time available, the use may proceed without any IRB approval.

Some manufacturers will agree to allow the use of the test article, but their policy requires "an IRB approval letter" before the test article will be shipped. If it is not possible to convene a quorum of the IRB within the time available, some IRBs have sent to the sponsor a written statement that the IRB is aware of the proposed use and considers the use to meet the requirements of 21 CFR 56.104(c). Although, this is not an "IRB approval," the acknowledgment letter has been acceptable to manufacturers and has allowed the shipment to proceed.

### **Exception From Informed Consent Requirement**

Even for an emergency use, the investigator is required to obtain informed consent of the subject or the subject's legally authorized representative unless both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing all of the following [21 CFR 50.23(a)]:

1. The subject is confronted by a life-threatening situation necessitating the use of the test article.
2. Informed consent cannot be obtained because of an inability to communicate with, or obtain legally effective consent from, the subject.
3. Time is not sufficient to obtain consent from the subject's legal representative.
4. No alternative method of approved or generally recognized therapy is available that provides an equal or greater likelihood of saving the subject's life.

If, in the investigator's opinion, immediate use of the test article is required to preserve the subject's life, and if time is not sufficient to obtain an independent physician's determination that the four conditions above apply, the clinical investigator should make the determination and, within 5 working days after the use of the article, have the determination reviewed and evaluated in writing by a physician who is not participating in the clinical investigation. The investigator must notify the IRB within 5 working days after the use of the test article [21 CFR 50.23(c)].

Under all circumstances, the Physician must file a written report with the RSPP Office within 5 working days of the use.

### **Obtaining an Emergency IND**

The emergency use of an unapproved investigational drug or biologic requires an IND. If the intended subject does not meet the criteria of an existing study protocol, or if an approved study protocol does not exist, the usual procedure is to contact the manufacturer and determine if the drug or biologic can be made available for the emergency use under the company's IND.

The need for an investigational drug or biologic may arise in an emergency situation that does not allow time for submission of an IND. In such a case, FDA may authorize shipment of the

test article in advance of the IND submission. Requests for such authorization may be made by telephone or other rapid communication means [21 CFR 312.36].

FDA allows one-time, single use of an investigational article in an emergency situation. If there is the possibility of a similar emergent need occurring in the future, a formal protocol must be developed and submitted for IRB review and approval for the investigational article's subsequent use at Aurora Health Care.